Entera Bio Lands $10M to Push Oral Osteoporosis Drug into Phase 3

TEL AVIV, Israel – April 02, 2026 – Clinical-stage biotechnology company Entera Bio Ltd. (Nasdaq: ENTX) today announced it has secured a crucial $10.0 million in funding through a direct investment led by the specialist life sciences hedge fund BVF Partners L.P. The capital infusion is earmarked to advance the company's lead candidate, EB613, into a pivotal Phase 3 registrational study, moving one of the industry's first potential oral bone-building therapies for osteoporosis significantly closer to reality.

The private placement, which closed today, has the potential to yield up to $24.5 million in total proceeds if all associated warrants are exercised. This financing provides a critical runway for Entera Bio to initiate its most ambitious clinical trial to date and represents a major vote of confidence from a seasoned biotech investor in the company’s proprietary oral peptide technology.

A Strategic Infusion for a Pivotal Trial

The financial terms of the deal reveal a carefully structured investment designed to support long-term development. Entera Bio issued 7,827,789 units at a purchase price of $1.2775 per unit. Each unit consists of one ordinary share (or a pre-funded warrant) and a five-year warrant to purchase one and a half ordinary shares at an exercise price of $1.24. This exercise price reflects an 11.7% premium over the company's closing price on March 31, 2026, signaling investor optimism in the company's future valuation.

The initial $10.0 million in gross proceeds provides immediate capital. The additional $14.5 million, contingent on the cash exercise of all warrants, offers a substantial, non-dilutive follow-on funding mechanism as the company hits future milestones. The warrants become exercisable six months after the closing date, aligning with the company’s projected timeline for advancing its clinical programs.

For a clinical-stage company like Entera Bio, which reported having cash to support operations through the middle of the third quarter of 2026, this infusion is transformative. It not only funds the direct costs of initiating the large-scale Phase 3 study for EB613 but also strengthens the company's balance sheet, providing stability in a notoriously volatile biotech market.

Redefining Osteoporosis Care with an Oral Anabolic

The funding’s primary target, EB613, aims to address a significant unmet need in the multi-billion dollar osteoporosis market. While numerous treatments exist, the most potent bone-building (anabolic) therapies, such as Forteo® (teriparatide), are all administered via subcutaneous injection. This creates barriers to patient adherence and convenience, leaving a large portion of the market underserved.

EB613 is being developed as the first-ever once-daily oral tablet version of teriparatide. A successful oral anabolic could revolutionize the standard of care, dramatically expanding the market by offering an effective, patient-friendly alternative to daily or monthly injections. The potential for such a drug has been a long-sought goal in metabolic bone disease.

A key factor de-risking the path forward for EB613 is a critical agreement Entera Bio secured with the U.S. Food and Drug Administration (FDA) in mid-2025. The agency agreed that total hip bone mineral density (BMD) at 12 months can serve as the primary endpoint for the Phase 3 trial. This is a monumental shift from traditional, longer, and more expensive fracture-based endpoints, which have historically slowed osteoporosis drug development. This streamlined regulatory path significantly shortens the trial duration and reduces the number of patients required, making the study more efficient and cost-effective.

Entera Bio plans to initiate the Phase 3 study, which will enroll approximately 750 postmenopausal women, in late 2026. Based on the 12-month endpoint, the company projects top-line results could be available as early as the second half of 2028, accelerating the potential timeline to market approval.

The BVF Endorsement: A Bet on Platform Technology

The investment by BVF Partners is more than just a financial transaction; it is a powerful endorsement of Entera Bio’s core scientific platform. Founded in 1993, BVF Partners is a highly respected investment firm known for its deep scientific diligence and long-term bets on small-to-mid-cap biotechnology companies with disruptive technologies. Their decision to lead this financing round suggests strong conviction in Entera’s proprietary N-Tab® technology.

The N-Tab® platform is the engine behind Entera's pipeline, designed to overcome the long-standing challenge of formulating peptides and proteins—large-molecule drugs typically degraded by the digestive system—into oral tablets. If successful with EB613, it would provide powerful clinical validation for the entire platform.

This technology is not limited to osteoporosis. Entera is also leveraging N-Tab® to develop the first oral treatments for hypoparathyroidism (EB612), obesity (an oral oxyntomodulin), and short bowel syndrome. BVF's investment can be seen as a strategic bet that if Entera can crack the code for oral teriparatide, it holds the key to unlocking a new class of oral biologic medicines across multiple high-value therapeutic areas.

Fortifying the Balance Sheet for the Road Ahead

The market has reacted positively to the news, with Entera Bio's stock (ENTX) surging over 25% in the past week. This reflects investor relief and optimism, as the financing removes immediate financial overhang and provides a clear path for the company to execute on its most important clinical asset. Prior to the deal, Entera's financial runway was a key concern for investors, a common challenge for development-stage biotechs that have not yet generated product revenue.

With this capital, Entera Bio is now in a much stronger position. The company can confidently commit resources to trial initiation, manufacturing scale-up for the new single-tablet formulation of EB613, and other critical pre-launch activities. The strengthened balance sheet provides the company with enhanced negotiating leverage in potential future partnerships and insulates it from the need to raise capital under less favorable market conditions.

With a clearer regulatory pathway, a fortified balance sheet, and the backing of a key institutional investor, Entera Bio's focus now shifts squarely to clinical execution. The initiation of the Phase 3 trial for EB613 later this year will mark a pivotal moment for the company, its investors, and millions of patients waiting for a more convenient and accessible bone-building therapy.